Medroxyprogesterone Acetate
"Medroxyprogesterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.
| Descriptor ID |
D017258
|
| MeSH Number(s) |
D04.210.500.745.745.654.829.395.700.500
|
| Concept/Terms |
Medroxyprogesterone Acetate- Medroxyprogesterone Acetate
- Depo-Medroxyprogesterone Acetate
- Depo Medroxyprogesterone Acetate
- 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate
- 6 alpha Methyl 17alpha hydroxyprogesterone Acetate
- (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione
- Medroxyprogesterone 17-Acetate
- Medroxyprogesterone 17 Acetate
|
Below are MeSH descriptors whose meaning is more general than "Medroxyprogesterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Medroxyprogesterone Acetate".
This graph shows the total number of publications written about "Medroxyprogesterone Acetate" by people in this website by year, and whether "Medroxyprogesterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Medroxyprogesterone Acetate" by people in Profiles.
-
Asked but not received: postpartum contraception access in opioid-using pregnant patients. Eur J Contracept Reprod Health Care. 2025 Dec; 30(6):335-343.
-
Progesterone receptor isoform modulation via enhancer activation regulates progesterone signaling in endometrial stromal cells. F S Sci. 2025 11; 6(4):397-413.
-
Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC). Contraception. 2022 08; 112:11-13.
-
Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women. J Gerontol A Biol Sci Med Sci. 2020 02 14; 75(3):537-544.
-
Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial. Contraception. 2018 09; 98(3):193-198.
-
Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception. 2018 03; 97(3):198-204.
-
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Clin Obstet Gynecol. 2016 03; 59(1):30-52.
-
MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer Cell. 2014 Jul 14; 26(1):92-105.
-
Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception. 2014 May; 89(5):352-6.
-
Progesterone signaling inhibits cervical carcinogenesis in mice. Am J Pathol. 2013 Nov; 183(5):1679-1687.